The Company noted it will provide more details on its 2021 outlook during the webcast scheduled for 9:00 a.m. There will be a question and answer section following the company’s prepared remarks. For the same reasons, the Company is unable to address the probable significance of the unavailable information. 4 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.

The company approached Avient with the question: how can we continue to meet premium brand owners’ needs while improving our own profitability? To learn more about Gravi-Tech™ solutions, contact Avient at +1.844.4AVIENT (1.844.428.4368) or visit www.avient.com.

The company is headquartered in Worms, Germany, with subsidiaries in Spain and Turkey supplying more than 50 countries worldwide. In addition, the GLS TPE from Avient passed migration, extraction and sensory testing by Nehring Institute as required by food contact regulations (EU) 10/2011 and FDA 177.1210.

MATERIAL REDUCES COSTS WITH LOWER SPECIFIC GRAVITY, AND HIGHER FLOW THAN COMPETITIVE TPV © 2021, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 To learn more about Versalloy™ Thermoplastic Vulcanizate, contact Avient at +1.844.4AVIENT (1.844.428.4368) or visit avient.com. The company also sought a vendor who could provide rapid delivery and reliable material supply to avoid production delays.

ROBOTIC EMULATION ENABLES PERSONALIZED PROSTHETICS WITH COMPOSITES Photo courtesy of the DoD Center for the Intrepid COMPOSITE SPRINGS PROVIDE FLEXIBILITY IN PROSTHETIC PERFORMANCE AND DESIGN © 2022, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 To learn more, please contact Avient at 1.844.4AVIENT (1.844.428.4368) or visit www.avient.com. Enter Humotech, a company focused on accelerating the discovery of innovative real-world solutions to enhance and augment human mobility through research and development of prostheses, exoskeletons, and other wearable machines.

as applicable) 4.2.2 Customer Description 4.2.3 Manufacturer’s Product Code 4.2.4 Manufacturer's Lot Number 4.2.5 Quantity and Units (Example 25 lbs.) 4.2.6 Company Name 4.2.7 Date of Manufacture 4.2.8 Expiration Date (as applicable) 5.0 SUPPORTING DOCUMENTATION 5.1 Certification: Each shipment of product will be accompanied by a Certification that, at the time of shipment, the material conforms to the Product Specifications. 5.1.1 Certification document will include: 5.1.1.1 Customer Part Number 5.1.1.2 Customer Purchase Order Number 5.1.1.3 Customer Material Description 5.1.1.4 Manufacturer's Lot Number 5.1.1.5 Total quantity shipped (with units) 5.1.1.6 Test values (as applicable) 5.1.2 Certification will be sent with each product shipment, addressed to the Customer’s shipping location and/or electronically sent to appropriate Customer contact. 5.1.3 The Certification document may contain test values conducted by NEU on the product for those characteristics listed under certification. 5.2 Safety Data Sheets: A Safety Data Sheet will be made available upon request or may be available on NEU’s website. Such inquiries by NEU do not transfer supplier control responsibilities to NEU. 8.0 CHANGE NOTIFICATION 8.1 General Notification 8.1.1 NEU will notify the Customer of the following changes to all NEU compounded materials: 8.1.1.1 Product nomenclature 8.1.1.2 Product Specifications 8.1.1.3 Manufacturing site 8.1.2 All notifications will be given to the purchasing contact at the purchasing locations of the products supplied.

Requirements: Skin contact colorant certified for ISO 10993 biocompatibility Solution: OnColor™ HC Plus, MEVOPUR® 5. Requirements: USP Class VI skin contact colorant for drug differentiation Solution: OnColor™ HC, MEVOPUR® 4 Button 5 Batch or SKU identifier Safety and trigger cap 6 DRUG CONCENTRATION 1 DRUG CONCENTRATION 2 DRUG CONCENTRATION 3 Patient Handling Age or certain disease states can severely limit patient dexterity making the self-administration of medication difficult and frustrating. Our company is a great place to work.

The Company noted it will provide more details on its 2021 outlook during the webcast scheduled for 9:00 a.m. There will be a question and answer session following the company’s presentation and prepared remarks. For the same reasons, the Company is unable to address the probable significance of the unavailable information. 6 Investor Relations Contact: Giuseppe (Joe) Di Salvo Vice President, Treasurer and Investor Relations Avient Corporation +1 440-930-1921 giuseppe.disalvo@avient.com Media Contact: Kyle G.

Investor Relations Contact: Eric R. Swanson, Director, Investor Relations, PolyOne Corporation, +1 440-930-1018, eric.swanson@avient.com, Media Contact: Kyle G. Investor Contacts

Vermijd daarom onnodig contact met concurrenten. 3. subject= http://avient.ethicspoint.com http://www.Avient.com/company/policies-and-governance/ethics-hotline http://www.Avient.com/company/policies-and-governance/ethics-hotline 1. Vermijd onnodig contact met concurrenten. 2.